Impact of Targeted Testing for Latent Tuberculosis Infection Using Commercially Available Diagnostics | Zendy

James D. Mancuso | Zendy; David R. Tribble | Zendy; Gerald H. Mazurek | Zendy; Yuanzhang Li | Zendy; Cara Olsen | Zendy; Naomi Aronson | Zendy; Lawrence Geiter | Zendy; David A. Goodwin | Zendy; Lisa W. Keep | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Targeted Testing for Latent Tuberculosis Infection Using Commercially Available Diagnostics

Author(s) -

James D. Mancuso,

David R. Tribble,

Gerald H. Mazurek,

Yuanzhang Li,

Cara Olsen,

Naomi Aronson,

Lawrence Geiter,

David A. Goodwin,

Lisa W. Keep

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir321

Subject(s) - medicine , tuberculin , logistic regression , latent tuberculosis , tuberculosis , test (biology) , predictive value of tests , mycobacterium tuberculosis , pathology , paleontology , biology

The interferon-γ release assays (IGRAs) are increasingly being used as an alternative to the tuberculin skin test (TST). Although IGRAs may have better specificity and certain logistic advantages to the TST, their use may contribute to overtesting of low-prevalence populations if testing is not targeted. The objective of this study was to evaluate the accuracy of a risk factor questionnaire in predicting a positive test result for latent tuberculosis infection using the 3 commercially available diagnostics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research